Apixaban safer than rivaroxaban in AF with liver disease, doctors say
Doctors can be reassured that apixaban is safe for patients with AF and liver disease, a retrospective cohort study suggests. The Harvard University-led study found…
Tag: Non-vitamin K oral anticoagulant (NOAC)
Prolonged NOACs beat warfarin for lowering recurrent VTE risk: study
Patients prescribed extended anticoagulation for VTE have a lower risk of recurrent VTE with NOACs compared to warfarin, according to a study in JAMA Network…
Anticoagulant proves ‘promising’ in reducing dementia risk
Australian study shows AF patients on NOACs are less likely to experience cognitive decline than those on warfarin.
Oral glucocorticoids plus NOACs ‘nearly doubles GI bleeding risk’
The combination of drugs is common and there is a dose-response relationship, researchers say.
Adding a NOAC to aspirin ‘reduces events after revascularisation’
New results from the VOYAGER PAD trial shows a benefit with no increase in bleeds.
Two-year lag in anticoagulation ‘common’ in high-risk AF
Patients are missing out on timely review of their stroke risk in primary care, a study suggests.
Warfarin might raise the risk of joint replacement: study
The analysis in people with AF suggests a NOAC might be the better option for those at risk of osteoarthritis, authors say.
Bleeding in anticoagulated patients ‘might flag cancer’
Emerging evidence suggests patients with AF who have a bleed should probably be investigated for malignancy, cardiologists warn.
Combination therapy ‘reduces risk of vascular events’ in PAD
A secondary trial analysis shows low-dose rivaroxaban and aspirin benefit high-risk patients with lower extremity PAD, authors say.
Apixaban is safer than rivaroxaban in AF: study
Choosing between the two drugs is a choice between thrombotic or haemorrhagic risk.
